vs

Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and Fulgent Genetics, Inc. (FLGT). Click either name above to swap in a different company.

BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $71.1M, roughly 1.6× Fulgent Genetics, Inc.). On growth, BYLINE BANCORP, INC. posted the faster year-over-year revenue change (9.0% vs -3.2%). Over the past eight quarters, BYLINE BANCORP, INC.'s revenue compounded faster (6.4% CAGR vs 0.1%).

Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.

Fulgent Genetics, Inc. is a molecular diagnostics technology firm that develops and offers genetic testing services including carrier screening, oncology testing, infectious disease detection, and hereditary condition analysis, serving clinical providers, pharma firms, research institutions and public health groups primarily in North America.

BY vs FLGT — Head-to-Head

Bigger by revenue
BY
BY
1.6× larger
BY
$112.4M
$71.1M
FLGT
Growing faster (revenue YoY)
BY
BY
+12.2% gap
BY
9.0%
-3.2%
FLGT
Faster 2-yr revenue CAGR
BY
BY
Annualised
BY
6.4%
0.1%
FLGT

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BY
BY
FLGT
FLGT
Revenue
$112.4M
$71.1M
Net Profit
$37.6M
Gross Margin
30.2%
Operating Margin
21.1%
Net Margin
33.4%
Revenue YoY
9.0%
-3.2%
Net Profit YoY
33.0%
EPS (diluted)
$0.83
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BY
BY
FLGT
FLGT
Q1 26
$112.4M
$71.1M
Q4 25
$117.0M
$83.3M
Q3 25
$115.7M
$84.1M
Q2 25
$110.5M
$81.8M
Q1 25
$103.1M
$73.5M
Q4 24
$104.7M
$76.2M
Q3 24
$101.8M
$71.7M
Q2 24
$99.4M
$71.0M
Net Profit
BY
BY
FLGT
FLGT
Q1 26
$37.6M
Q4 25
$34.5M
$-23.4M
Q3 25
$37.2M
$-6.6M
Q2 25
$30.1M
$-19.0M
Q1 25
$28.2M
$-11.5M
Q4 24
$30.3M
$-5.9M
Q3 24
$30.3M
$-14.6M
Q2 24
$29.7M
$-8.7M
Gross Margin
BY
BY
FLGT
FLGT
Q1 26
30.2%
Q4 25
39.1%
Q3 25
42.2%
Q2 25
42.1%
Q1 25
38.6%
Q4 24
41.8%
Q3 24
37.3%
Q2 24
37.3%
Operating Margin
BY
BY
FLGT
FLGT
Q1 26
21.1%
Q4 25
40.1%
-43.5%
Q3 25
43.1%
-18.3%
Q2 25
35.2%
-24.1%
Q1 25
36.4%
-26.9%
Q4 24
38.6%
-21.2%
Q3 24
39.3%
-23.8%
Q2 24
40.4%
-26.6%
Net Margin
BY
BY
FLGT
FLGT
Q1 26
33.4%
Q4 25
34.1%
-28.1%
Q3 25
32.1%
-7.9%
Q2 25
27.2%
-23.2%
Q1 25
27.4%
-15.7%
Q4 24
34.3%
-7.7%
Q3 24
29.8%
-20.4%
Q2 24
29.9%
-12.3%
EPS (diluted)
BY
BY
FLGT
FLGT
Q1 26
$0.83
$0.04
Q4 25
$0.77
Q3 25
$0.82
Q2 25
$0.66
Q1 25
$0.64
Q4 24
$0.68
Q3 24
$0.69
Q2 24
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BY
BY
FLGT
FLGT
Cash + ST InvestmentsLiquidity on hand
$198.4M
$23.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.3B
Total Assets
$9.9B
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BY
BY
FLGT
FLGT
Q1 26
$198.4M
$23.4M
Q4 25
$149.1M
$50.2M
Q3 25
$259.0M
$117.6M
Q2 25
$218.3M
$87.9M
Q1 25
$421.3M
$67.3M
Q4 24
$563.1M
$55.1M
Q3 24
$452.6M
$58.0M
Q2 24
$730.5M
$65.1M
Stockholders' Equity
BY
BY
FLGT
FLGT
Q1 26
$1.3B
Q4 25
$1.3B
$1.1B
Q3 25
$1.2B
$1.1B
Q2 25
$1.2B
$1.1B
Q1 25
$1.1B
$1.1B
Q4 24
$1.1B
$1.1B
Q3 24
$1.1B
$1.1B
Q2 24
$1.0B
$1.1B
Total Assets
BY
BY
FLGT
FLGT
Q1 26
$9.9B
$1.2B
Q4 25
$9.7B
$1.2B
Q3 25
$9.8B
$1.2B
Q2 25
$9.7B
$1.2B
Q1 25
$9.6B
$1.2B
Q4 24
$9.5B
$1.2B
Q3 24
$9.4B
$1.2B
Q2 24
$9.6B
$1.2B

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons